AngioDynamics Company Leadership
| ANGO Stock | USD 10.54 -0.17 -1.59% |
About 75 percent of all AngioDynamics' insiders are aggressively buying. The analysis of insiders' sentiment of trading AngioDynamics stock suggests that quite a few insiders are very bullish at this time. AngioDynamics employs about 675 people.
| James Clemmer CEO President CEO, Director |
| Chad Campbell President Senior Vice President and General Manager, Vascular Access |
Insider Sentiment
Mostly Buying
Selling | Buying |
Latest Trades
| 2025-10-21 | Lawrence T Weiss | Acquired 10000 @ 11.81 | View | ||
| 2025-10-20 | Debbie Wasserman Schultz | Disposed @ 11.82 | |||
| 2025-10-13 | Stephen A Trowbridge | Acquired 890 @ 11.16 | View | ||
| 2025-10-09 | James C Clemmer | Acquired 10000 @ 11.15 | View |
Monitoring insider sentiment in AngioDynamics can give investors another window into how people closest to the business may be assessing current prospects. The value here is transparency: investors can review the pattern without assuming every insider transaction predicts the next price move.
Acquired vs Disposed
Filed vs Not Filed
The insider-sentiment profile for AngioDynamics is usually inferred from how executives, directors, and beneficial owners buy or sell shares over time. Used properly, insider trading data is contextual rather than absolute because corporate insiders can transact for several reasons that are not purely directional.
AngioDynamics | Build portfolio with AngioDynamics Stock |
AngioDynamics' Workforce Through the Years
A workforce review of AngioDynamics matters because hiring and staffing trends often say something about growth plans, cost discipline, and management expectations. Based on the current model, AngioDynamics is expected to maintain about 680 employees by April 2026.Macro event markers
latest congressional trading
Government-trading disclosures involving AngioDynamics matter because they give the market another transparency channel for politically exposed investors. Used properly, this data is another governance and disclosure signal rather than a standalone trading system.
| 2025-10-27 | Representative Debbie Wasserman Schultz | Acquired under $15,000 | Verify |
Management Team Effectiveness
The company has return on total asset (ROA) of -4.6 % which means that on every $100 spent on assets, it lost $4.6. This is very low relative to industry peers. Similarly, it shows a return on stockholder's equity (ROE) of -15.26 %, which implies that shareholder value decreased during the period.As of March 24, 2026, Common Stock Shares Outstanding is anticipated to decline to approximately 30.6 M. In addition to that, Net Loss is estimated to increase to approximately -44.8 M.
Stock Institutional Investors
AngioDynamics has 96.55% institutional ownership and 12.30% insider stake. Annual revenue is about 292.5 Million. This mix shapes how the stock trades around earnings. The business currently sits in the Health Care sector and the Health Care Equipment & Services industry. Volume spikes around index rebalance dates are worth monitoring given the high institutional share.
| Shares | Geode Capital Management, Llc | 2025-12-31 | 969.9 K | State Street Corp | 2025-09-30 | 956.9 K | Dimensional Fund Advisors, Inc. | 2025-12-31 | 916.3 K | Renaissance Technologies Corp | 2025-12-31 | 843.1 K | Millennium Management Llc | 2025-12-31 | 842.5 K | Arrowstreet Capital Limited Partnership | 2025-12-31 | 752.9 K | Paradigm Capital Management, Inc. | 2025-12-31 | 678.2 K | Phocas Financial Corp | 2025-12-31 | 606.3 K | Pier Capital, Llc | 2025-12-31 | 571.9 K | Blackrock Inc | 2025-09-30 | 3.5 M | Point72 Asset Management, L.p. | 2025-12-31 | 2.8 M |
Insider Trading Activities
Tracking AngioDynamics' insider filings adds context. Executives often respond to business conditions well before market sentiment shifts. It trades on NASDAQ in US. The business currently sits in the Healthcare sector and the Medical Instruments & Supplies industry.
Outstanding Bonds
Outstanding bonds linked to AngioDynamics can tell investors a great deal about how the company finances itself beyond common equity markets. Longer-dated obligations can improve financing stability, but they also leave investors more exposed if the underlying business weakens before the debt matures.
Corporate Filings
13A | 13th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 10th of February 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 9th of February 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 3rd of February 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 14th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of January 2026 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2025 An amended filing to the original Schedule 13G | ViewVerify |
Shares in Circulation | First Issued 2003-03-31 | Previous Quarter 41.2 M | Current Value 41.4 M | Average Shares Outstanding 30.6 M | Quarterly Volatility 9.8 M |
Macro event markers
Holders Distribution
Institutional investors in AngioDynamics typically operate with more research capacity, technology, and trading scale than retail holders, which is why their activity can materially affect price behavior. The better interpretation comes from watching concentration, turnover, and changes in holder behavior instead of assuming institutional ownership is automatically bullish.
Market Cap and Value
Workforce Comparison
AngioDynamics lands at #4 in number of employees compared to key competitors. The total workforce of Health Care industry is presently estimated at about 9,320. AngioDynamics holds roughly 675 in number of employees claiming about 7% of equities under Health Care sector.
Profit Margins
The company has Profit Margin (PM) of -9.0 %, which implies that overhead and cost of goods exceed revenue generation. This is very low relative to industry peers. Similarly, it shows Operating Margin (OM) of -3.0 %, which means operating inefficiencies are consuming more than the revenue earned.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.58 | 0.62 |
|
|
Insider Trading History
The insider timeline for AngioDynamics shows how management behavior has tracked against the stock's price over time. Pattern analysis matters more than any single trade. The full record tells the real story.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-09-01 | 1.1875 | 19 | 16 | 948,105 | 27,990 |
| 2024-09-01 | 1.7 | 34 | 20 | 1,056,757 | 63,960 |
| 2023-09-01 | 0.881 | 37 | 42 | 1,361,559 | 450,619 |
| 2022-09-01 | 1.8667 | 28 | 15 | 220,408 | 121,779 |
| 2022-06-01 | 0.2 | 1 | 5 | 6,022 | 23,057 |
| 2022-03-01 | 1.0 | 2 | 2 | 11,000 | 1,777 |
| 2021-12-01 | 0.3333 | 2 | 6 | 22,748 | 49,943 |
| 2021-09-01 | 0.9796 | 48 | 49 | 726,626 | 388,157 |
| 2021-06-01 | 0.4 | 2 | 5 | 19,351 | 36,552 |
| 2021-03-01 | 1.0 | 2 | 2 | 73,000 | 7,027 |
| 2020-09-01 | 1.0 | 22 | 22 | 661,809 | 101,791 |
| 2020-03-01 | 1.0 | 2 | 2 | 23,580 | 980.00 |
| 2019-12-01 | 7.0 | 7 | 1 | 108,408 | 736.00 |
| 2019-09-01 | 0.75 | 30 | 40 | 549,233 | 448,351 |
| 2019-06-01 | 0.2857 | 2 | 7 | 13,300 | 27,096 |
| 2018-09-01 | 1.7857 | 25 | 14 | 292,745 | 24,178 |
| 2018-06-01 | 0.4 | 4 | 10 | 41,650 | 67,931 |
| 2017-12-01 | 0.6 | 3 | 5 | 41,409 | 79,691 |
| 2017-09-01 | 1.8421 | 35 | 19 | 453,386 | 166,882 |
| 2017-06-01 | 0.0455 | 1 | 22 | 14,000 | 4,862,567 |
| 2017-03-01 | 0.5 | 1 | 2 | 14,000 | 28,000 |
| 2016-12-01 | 0.3333 | 2 | 6 | 50,000 | 5,000,000 |
| 2016-09-01 | 1.2727 | 28 | 22 | 389,948 | 4,624,865 |
| 2016-06-01 | 0.75 | 3 | 4 | 500,000 | 17,806 |
| 2015-09-01 | 1.1143 | 39 | 35 | 429,609 | 125,124 |
| 2015-06-01 | 2.0 | 2 | 1 | 19,649 | 4,649 |
| 2015-03-01 | 0.3333 | 1 | 3 | 18,100 | 36,619 |
| 2014-09-01 | 1.8 | 36 | 20 | 416,843 | 43,453 |
| 2014-06-01 | 1.0 | 2 | 2 | 16,500 | 16,448 |
| 2013-12-01 | 2.8571 | 20 | 7 | 212,407 | 52,693 |
| 2013-09-01 | 2.0625 | 33 | 16 | 331,424 | 24,965 |
| 2013-03-01 | 3.0 | 9 | 3 | 216,808 | 5,946 |
| 2012-12-01 | 0.3846 | 5 | 13 | 68,000 | 36,718 |
| 2012-09-01 | 3.0 | 33 | 11 | 268,247 | 14,955 |
| 2012-06-01 | 3.6667 | 11 | 3 | 104,209 | 4,589 |
| 2012-03-01 | 0.5455 | 6 | 11 | 103,000 | 42,916 |
| 2011-12-01 | 4.0 | 4 | 1 | 322,500 | 200,000 |
| 2011-09-01 | 3.7143 | 26 | 7 | 629,617 | 12,483 |
| 2011-06-01 | 1.0 | 1 | 1 | 2,091 | 2,091 |
| 2011-03-01 | 2.5 | 5 | 2 | 103,000 | 10,119 |
| 2010-12-01 | 2.5 | 5 | 2 | 151,000 | 50,000 |
| 2010-09-01 | 1.8333 | 22 | 12 | 295,250 | 75,702 |
| 2010-06-01 | 3.0 | 3 | 1 | 52,591 | 2,091 |
| 2010-03-01 | 0.5 | 2 | 4 | 4,500 | 306,298 |
| 2009-12-01 | 0.8 | 4 | 5 | 55,628 | 25,152 |
| 2009-09-01 | 11.5 | 23 | 2 | 226,709 | 50,800 |
| 2009-06-01 | 3.0 | 3 | 1 | 9,091 | 2,091 |
| 2009-03-01 | 2.0 | 10 | 5 | 399,693 | 22,267 |
| 2008-12-01 | 1.0 | 1 | 1 | 21,000 | 0.00 |
| 2008-09-01 | 18.0 | 18 | 1 | 151,313 | 20,000 |
| 2008-06-01 | 3.0 | 3 | 1 | 6,106 | 2,091 |
| 2008-03-01 | 2.0 | 2 | 1 | 5,000 | 2,000 |
| 2007-09-01 | 13.5 | 27 | 2 | 239,775 | 10,200 |
| 2007-06-01 | 1.0 | 4 | 4 | 53,500 | 12,368 |
| 2007-03-01 | 0.1176 | 2 | 17 | 5,955 | 71,743 |
| 2006-12-01 | 0.5333 | 8 | 15 | 185,546 | 173,159 |
| 2006-09-01 | 0.7619 | 16 | 21 | 61,993 | 58,182 |
| 2006-06-01 | 0.5714 | 8 | 14 | 12,624 | 23,686 |
| 2006-03-01 | 0.5 | 11 | 22 | 30,500 | 59,000 |
| 2005-12-01 | 0.3421 | 13 | 38 | 20,062 | 63,124 |
| 2005-09-01 | 0.5517 | 16 | 29 | 78,900 | 62,112 |
| 2005-06-01 | 0.6296 | 17 | 27 | 51,838 | 53,103 |
| 2005-03-01 | 0.5 | 11 | 22 | 28,546 | 57,092 |
| 2004-12-01 | 1.3333 | 8 | 6 | 1,735,843 | 9,242,006 |
| 2004-06-01 | 1.1667 | 7 | 6 | 78,400 | 99,319 |
Notable Stakeholders
An AngioDynamics stakeholder is any individual or group with an interest in the outcome of the business, which is why stakeholder analysis can reveal who may influence strategy and oversight. The stronger interpretation comes from connecting stakeholder presence with management behavior, governance patterns, and changes in the operating story.
| James Clemmer | President CEO, Director | Profile | |
| Chad Campbell | Senior Vice President and General Manager, Vascular Access | Profile | |
| David Helsel | Senior Vice President - Global Operations | Profile | |
| Warren Nighan | Senior Vice President-Senior Vice President Quality & Regulatory Affairs | Profile | |
| Kim Seabury | Senior Vice President Information Technology | Profile | |
| Benjamin Davis | Senior Vice President Business Development | Profile | |
| Stephen Trowbridge | Sr. VP, General Counsel and Assistant Secretary | Profile | |
| Lawrence Weiss | Chief VP | Profile | |
| Jake Brumbaugh | Global MarketingOncology | Profile | |
| Laura Piccinini | Senior International | Profile | |
| Scott Centea | Senior Therapies | Profile | |
| Richard Rosenzweig | Gen VP | Profile | |
| Marna BronfenMoore | Senior Resources | Profile | |
| Juan Serna | Senior Affairs | Profile | |
| Saleem Cheeks | Vice Communications | Profile |
Management Information & Data Sources
AngioDynamics is a small-cap company in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care. Executive review focuses on insiders, senior management, and employee signals. Employee count and organizational scale can help frame operating leverage and execution complexity. CEO is James Clemmer with 675 employees and 15 reported executives.
This section for AngioDynamics is built from periodic company reporting and market reference feeds, with reporting definitions aligned before display. Sell-side coverage, where present, supplements the data shown. Values may update on different source schedules. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Workforce metrics tied to AngioDynamics offer a useful way to test whether headcount and economic output are moving in a productive direction. Used correctly, manpower metrics can highlight whether growth is being supported by better productivity or by heavier staffing costs.
AngioDynamics Manpower Efficiency
Return on AngioDynamics Manpower
| Revenue Per Employee | 433.3K | |
| Revenue Per Executive | 19.5M | |
| Net Loss Per Employee | 50.4K | |
| Net Loss Per Executive | 2.3M | |
| Working Capital Per Employee | 136.5K | |
| Working Capital Per Executive | 6.1M |